Eserler a. Uluslararası hakemli dergilerde yayımlanan makaleler: sadik, S., Onoglu, as., M. M. Inal

Download 248.43 Kb.
Size248.43 Kb.
1   2   3

L10.10. Ceyhan, C., Turgut, H., "Acute Transient Diastolic Dysfunction Induced By 5-Fluorouracil Treatment: A Case Report”, Journal of Cardiac Research TM, 32: (2005).

L10.11. Lyseng-Williamson, KA., Duggan, ST., Keating, GM., “Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies”, BioDrugs, 27 (5): 533-540 (2013).

L10.12. Hartung, GA., Mansoori, GA., “In vivo General Trends, Filtration and Toxicity of Nanoparticles”, Journal of Nanomaterials & Molecular Nanotechnology, 2 (3): 1-21 (2013).

L10.13. Zhenhua, Z., Jingbo, W., “Cytotoxicity Effect of Thermo-chemotherpy with Pegylated Liposomal Doxorubicin on Human Esophageal Carcinoma in vitro”, Cancer Research on Prevention and Treatment, 38 (7): (2011).

L10.14. Zhang, Y., Zhang, Q., Zeng, SX., Hao, Q., Lu, H., “Inauhzin Sensitizes p53-Dependent Cytotoxicity and Tumor Suppression of Chemotherapeutic Agents”, Neoplasia, 15 (5): 523–534 (2013).

L10.15. Mansoori, G.A., “In vivo General Trends, Filtration and Toxicity of Nanoparticles”, Journal of Nanomaterials & Molecular, 2013

L11 (A18). M.M. Inal, Incebiyik, A., Sanci, M., Yildirim, Y., Polat, M., Pilanci, B., Nayki, C., Camuzcuoglu, H., “Ovarian Cysts in Tamoxifen-Treated Women with Breast Cancer”, Eur J Obstet Gynecol Reprod Biol, 120 (1): 104-106 (2005).

L11.1. Fleming, JS., Beaugié, CR., Haviv, I., Chenevix-Trench, G., Tan, OL., “Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses”, Molecular and Cellular Endocrinology, 247 (1–2): 4–21 (2006).

L11.2. Peano, BJ., Crabtree, JS., Komm, BS., Winneker, RC., Harris, HA., “Effects of Various Selective Estrogen Receptor Modulators with or without Conjugated Estrogens on Mouse Mammary Gland”, Endocrinology, 150 (4): 1897-1903 (2009).

L11.3. Harris, HA., Chennathukuzhi, VM., Zhang, X., Mekonnen, B., et al. ”Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats”, The Journal of Steroid Biochemistry and Molecular Biology, 112 (1-3): 40–46 (2008).

L11.4. Lin, L., Shu-zhen, W., Zhen-yu, Z., Yan, Z., Hong-chuan, J., Jie, L., “Follow-up of benign gynecologic diseases in patients treated with tamoxifen for breast cancer”, National Medical Journal of China, 25: (2010).

L11.5. Baigent, A., Lashen, H., “Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer”, Fertility and Sterility, 95 (7): 2429.e5–2429.e7 (2011).

L11.6. Mofrad, MH., Shandiz, FH., Roodsare, FV., Toktam Moghima, T., “Evaluation of Ovarian Cysts in Breast Cancer Cases on Tamoxifen”, Asian Pacific J Cancer Prev, 11: 161-164 (2010).

L11.7. Qin Wu, Q., Xiaozhong, C., Yiyong, W., “Effects of Tamoxifen on uterus and ovary in patients with breast cancer”, Chongqing Medicine Journal, 36 (16): (2007).

L11.8. Oliva, P., Roncoroni, C., Radaelli, E., Brunialti, E., Rizzi, N., De Maglie, M., Scanziani, E., et al. “Global Profiling of TSEC Proliferative Potential by the Use of a Reporter Mouse for Proliferation”, Reproductive Sciences, 20 (2): 119-128 (2013).

L11.9. Yıldırım, Y., Toz, E., “The Effect of Long-term Tamoxifen Usage on the Lower PArt of Female Genital Tract in Breast Cancer Survivors: A Review”, Marmara Medical Journal, 20 (3): 196-201 (2007).

L11.10. Guastalla, J.P., Tredan, O., Ray-Coquard, I., Labidi, I., Bonnin, N., Bachelot, T. L “Hormonothérapie adjuvante (produits, durée) doit-elle être modulée par le profil biologique de la tumeur (niveau d’hormonosensibilité, statut d’HER2 et prolifération)”, Cancer, 2006, pp 385-399 (2006).

L11.11. Hsiao, W., Weimin, K., Xiunan, L., Yi, D., “Endocrine therapy for breast cancer and its impact on female genital mutilation”, The Chinese Journal of practical Gynecology and Obstetrics, 1 (3): 817-819 (2008).

L11.12. Zhonglin, F., Haiping, L., Cuizhi, G., Yun-Tao, L., “Changes of serum estradiol and follicular stimulating hormone after tamoxifen treatment in breast cancer cases”, Chinese Journal of Clinical Physicians, 1: (2012).

L11.13. Matiluko, AF., Crystal, AM., “Adnexal torsion in a postmenopausal woman on tamoxifen”, Trends Urology, Gynecol. Sexual Health, 14 (5): 30–32 (2009).

L12 (A17). M.M. Inal, Ertopcu, K., Ozelmas, I., “The Evaluation of 318 Intrauterine Pregnancy Cases with An Intrauterine Device”, Eur J Contracept Reprod Health Care, 10 (4): 266-271 (2005).

L12.1. Van Oppenraaij, RHF., Jauniaux, E., “Predicting adverse obstetric outcome after early pregnancy events and complications: a review”, Hum. Reprod. Update, 15 (4): 409-421 (2009).

L12.2. Merki-Feld, GS., Schwarz, D., Imthurn, B., Keller, PJ., “Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing IUD after correct insertion”, European Journal of Obstetrics & Gynecology and Reproductive Biology, 137 (1): 92–96 (2008).

L12.3. Ganer, H., Levy, A., Ohel, I., Sheiner, E., “Pregnancy outcome in women with an intrauterine contraceptive device”, American Journal of Obstetrics and Gynecology, 201 (4): 381.e1–381.e5 (2009).

L12.4. Yu, J., Li, J., Li, H., Li, J., Xie, C., Zhu, C., “Comparative study on contraceptive efficacy and clinical performance of the copper/low-density polyethylene nanocomposite IUD and the copper T220C IUD”, Contraception, 78 (4): 319–323 (2008).

L12.5. Snell, BJ., “Assessment and Management of Bleeding in the First Trimester of Pregnancy”, Journal of Midwifery & Women’s Health, 54 (6): 483–491 (2009).

L12.6. Brahmi, D., Steenland, MW., Renner, RM, Gaffield, ME., Curtis, KM., “Pregnancy outcomes with an IUD in situ: a systematic review”, Contraception, 85 (2): 131–139 (2012).

L12.7. Moschos, E., Twickler, DM, ”Intrauterine devices in early pregnancy: findings on ultrasound and clinical outcomes”, American Journal of Obstetrics and Gynecology, 204 (5): 427.e1–427.e6 (2011).

L12.8. Gyang, A., Mirando, S., “Gräfenberg ring retained for 15 years: A case report”, The European Journal of Contraception and Reproductive Health Care, 11 (4): 319-321 (2006).

L12.9. Owen, C., Sober, S., Schreiber, CA., “Controversies in family planning: desired pregnancy, IUD in situ and no strings visible”, Contraception, 88 (3): 330-3 (2013).

L12.10. Mirena IUD Lawsuit Moves, Mirena IUD Helpline Watches. "The Mirena IUD is Manufactured by Bayer..." (2013).

L12.11. Veloso, MD., Lobos, AG., Aliste, SN., Rojas, GC., García, MP., Matzler, PP., “Post-insertion ultrasonographic control of intrauterine device”, Rev Chil Obstet Ginecol, 76 (1): 15 – 20 (2011).

L12.12. Rowen, T., Creinin, MD., “Highlights (and lowlights) from the past year in contraception: the US unintended pregnancy rate and controversies in providing contraception”, Update: Contraception, 24 (8): 29-35 (2012).

L12.13. Dean, G., Goldberg, AB., Zieman, M., Barss, VA., “Overview Of Mirena IUD Complications, Medical Perspective”, Mirena IUD Lawsuit News, (2013).

L13. (A3). Taner, C., M. Inal, Basogul, O., Onoglu, A., Karanfil, C., Tinar, S., Ispahi, C., “Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an Oral Contraceptive in the Treatment of Hirsutism”, Gynecol Obstet Invest, 54 (2): 105-108 (2002).

L13.1. Koulouri, O., Conway, GS., “A systematic review of commonly used medical treatments for hirsutism in women”, Clinical Endocrinology, 68 (5): 800–805 (2008).

L13.2. Escobar-Morreale, HF., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., et al. “Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society”, Hum. Reprod. Update, 18 (2): 146-170 (2012).

L13.3. Castelo-Branco, C., Moyano, D., Gómez, O., Balasch, J., “Long-term safety and tolerability of flutamide for the treatment of hirsutism”, Fertility and Sterility, 91 (4): 1183–1188 (2009).

L13.4. Sahin, Y., Kelestimur, F., “Medical treatment regimens of hirsutism”, Reproductive BioMedicine Online, 8 (5): 538–546 (2004).

L13.5. Al-Robaee, A., Al-Zolibani, A., Al-Shobaili, HA., Aslam, M., “Update on hirsutism”, Acta Dermatoven APA, 17 (3): 103-119 (2008).

L13.6. Paradisi, R., Venturoli, S., “Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period”, Eur J Endocrinol, 163 (1): 139-147 (2010).

L13.7. Castelo-Branco, C., Cancelo, MJ., “Comprehensive clinical management of hirsutism”, Gynecological Endocrinology, 26 (7): 484-493 (2010).

L13.8. Lis-huang, M., Mei-yu, Y., Xiao-ke, W., “Treatment of adolescent polycystic ovary syndrome”, Foreign medical sciences (maternal and child health division), 16 (3): (2005).

L13.9. Lumachi, F., Zulian, E., Scaroni, C., “Cost-effective therapy in patients with idiopathic hirsutism”, Expert Review of Pharmacoeconomics & Outcomes Research, 4 (3): 297-306 (2004).

L13.10. Hartmann, KE., Jerome, RN., Lindegren, ML., et al. “Primary Care Management of Abnormal Uterine Bleeding”, Rockville (MD): Agency for Healthcare Research and Quality (US); Comparative Effectiveness Reviews, No. 96 (2013).

L13.11. Manieri, DC., Di Bisceglie, C., Brocato, L., “Terapia farmacologica di irsutismo e androgenizzazione”, L’Endocrinologo, 4 (3): 118-130 (2003).

L14. (A4). Vardar, E., Maral, I., M. Inal, Ozguder, O., Tasli, F., Postaci, H., “Comparison of Gram Stain and Pap Smear Procedures in the Diagnosis of Bacterial Vaginosis”, Infect Dis Obstet Gynecol, 10 (4): 203-207 (2002).

L14.1. Fitzhugh, VA., Heller, DS., “Significance of a diagnosis of microorganisms on pap smear”, J Low Genit Tract Dis, 12 (1): 40-51 (2008).

L14.2. Eriksson, K., Forsum, U., Bjornerem, A., Platz-Christensen, JJ., Larsson, PG., ”Validation of the use of Pap-stained vaginal smears for diagnosis of bacterial vaginosis”, APMIS, 115 (7): 809–813 (2007).

L14.3. Niño, LR., Manzanero, RZ., Urdaneta, JC., Martínez, VG., Maribel, N., “Bacterial vaginosis: evaluation of diagnostic methods”, Kasmera, 32 (1): 43-51, (2004).

L14.4. Eriksson, K., Adolfsson, A., Forsum, U., Larsson, PG., “The prevalence of BV in the population on the Åland Islands during a 15-year period”, APMIS, 118 (11): 903–908 (2010).

L14.5. Ngaojaruwong, N., Vuthiwong, C., et al. “Prevalence of Abnormal Papanicolaou Smear in Pregnant Women at Phramongkutklao Hospital”, Thai Journal of Obstetrics and Gynaecology, 16 (3): 179-185 (2008).

L14.6. Alves, VAF., Filho, AC., Namiyama, G., Filho, AL., et al. “Liquid-based cytology by DNA-Cytologic system (DCS) – efficacy in identification of vaginal microflora”, DST – J bras Doenças Sex Transm, 16 (4): 27-31 (2004).

L14.7. Eriksson, K., “Bacterial Vaginosis: Diagnosis, Prevalence, and Treatment”, Linköping University Electronic Press, Linköping, (2011).

L14.8. Karasahin, E., Gungor, S., Ceyhan, ST., Keskin, U., Baser, I., “The association of contraceptive usage with the frequency of the most common etiological agents of vaginal infection”, Balkan Military Medical Review, 11 (1): 34-39 (2008).

L15. (A15). Sehirali, S., M.M. Inal, Yildirim, Y., Balim, Z., Kosova, B., Karamizrak, T., Sanci, M., Topcuoglu, N., Tinar, S., “Prothrombin G20210A Mutation in Cases with Recurrent Miscarriage: A Study of the Mediterranean Population”, Arch Gynecol Obstet, 273 (3): 170-173 (2005).

L15.1. Toth, B., Vocke, F., Rogenhofer, N., Friese, K., Thaler, CJ., Lohse, P., “Paternal Thrombophilic Gene Mutations Are Not Associated with Recurrent Miscarriage”, American Journal of Reproductive Immunology, 60 (4): 325–332 (2008).

L15.2. Zoossmann-Diskin, A., Gazit, E., Peleg, L., Shohat, M., Turner, D., “Thrombophilic polymorphisms in Israel”, Blood Cells, Molecules, and Diseases, 41 (2): 230–233 (2008).

L15.3. Glueck, CJ., Pranikoff, J., Khan, N., Riaz, K., et al. “High factor XI, recurrent pregnancy loss, enoxaparin”, Fertility and Sterility, 94 (7): 2828–2831 (2010).

L15.4. Zoossmann-Diskin, A., “The origin of Eastern European Jews revealed by autosomal, sex chromosomal and mtDNA polymorphisms”, Biology Direct, 5 (1): 57-75 (2010).

L15.5. Zonouzi, AP., Chaparzadeh, N., Ghorbian, S., Sadaghiani, MM., et al. “The association between thrombophilic gene mutations and recurrent pregnancy loss”, Journal of Assisted Reproduction and Genetics, 30 (10): 1353-1359 (2013).

L15.6. Gawish, GEH., Al-Khamees, O., “Molecular Characterization of Factor V Leiden G1691A and Prothrombin G20210A Mutations in Saudi Females with Recurrent Pregnancy Loss”, J Blood Disorders Transf, 4 (6): 1-7 (2013).

L16. (A12). Yildirim, Y., Tinar, S., Yildirim, YK., M.M. Inal, “Comparison of Pituitary-Ovarian Function in Patients Who Have Undergone Successful Renal Transplantation and Healthy Women”, Fertil Steril, 83 (5): 1553-1556 (2005).

L16.1. Douglas, NC., Shah, M., Sauer, MV., “Fertility and Reproductive Disorders in Female Solid Organ Transplant Recipients”, Seminars in Perinatology, 31 (6): 332-338 (2007).

L16.2. Abe, T., Ichimaru, N., Okumi, M., Imamura, R., Isaka, Y., Takahara, S., Kokado, Y. Okuyama, A., “Pregnancy after renal transplantation: A single-center experience”, International Journal of Urology, 15 (7): 587–592 (2008).

L16.3. Richman, K., Gohh, R., “Pregnancy after renal transplantation: a review of registry and single-center practices and outcomes”, Nephrol. Dial. Transplant, 27 (9): 3428-3434 (2012).

L16.4. Gassen, DT., Herter, LD., Garcia, C., Marroni, R., Maiga Milagre, M., Barros, V., “Hormonal aspects of gynecological patients with transplanted kidney and Nefropathies”, Revista HCPA, 29 (3): (2009).

L16.5. Yıldırım, Y., Sönmez, S., Toz, E., İnal, M., Aykas, A., Uslu, A., “Solid organ (kidney, liver, pancreas-kidney, heart, lung and heart-lung) transplantations and pregnancy”, Marmara Medical Journal, 21 (1): 79-88 (2008).

L16.6. Kim, JM., Song, RK., Kim, MJ., Lee, DY., Jang, HR., Kwon, CHD., et al. “Hormonal Differences Between Female Kidney Transplant Recipients and Healthy Women With the Same Gynecologic Conditions”, Transplantation Proceedings, 44 (3): 740-743 (2012).

L16.7. Pietrzak, B., Wielgos, M., Kaminski, P., Jabiry-Zieniewicz, Z., Bobrowska, K., “Menstrual Cycle and Sex Hormone Profile in Kidney-Transplanted Women”, Neuroendocrinology Letters, 27 (1-2): 198-202 (2006).

L17. (A22). M.M. Inal, Yildirim, Y., Ertopcu, K., Ozelmas, I., “The Predictors of Retained Products of Conception Following First-trimester Pregnancy Termination with Manual Vacuum Aspiration”, Eur J Contracept Reprod Health Care, 11 (2): 98-103 (2006).

L17.1. Müngen, E., Dundar, O., Babacan, A., “Postabortion Doppler Evaluation of the Uterus; Incidence and Causes of Myometrial Hypervascularity”, JUM, 28 (8): 1053-1060 (2009).

L17.2. Kara, F., Dogan, NU., Bati, S, Demir, S., Durduran, Y., Celik, C., “Early surgical abortion: Safe and effective”, The European Journal of Contraception and Reproductive Health Care, 18 (2): 120-126 (2013).

L17.3. Russo, JA., DePiñeres, T., Gil, L., “Controversies in family planning: retained products of conception”, Contraception, 86 (5): 438-42 (2012).

L17.4. Maged, A., Gaffar, H., Mostafa, W., “Role of transvaginal ultrasound in detection of retained products of conception after abortion”, Saudi J Health Sci, 1 (3): 151-155 (2012).

L17.5. Mentula, M., “Second trimester medical termination of pregnancy: procedure, immediate complications and the risk of repeat termination”, University of Helsinki, Faculty of Medicine, Institute of Clinical Medicine, Doctoral Thesis (2012).

L18. (A14). Yildirim, Y., M. Inal, Tinar S., “Necrotizing Fasciitis after Abdominal Hysterectomy: A Report on Five Cases”, Arch Gynecol Obstet, 273 (2): 126-128 (2005).

L18.1. Bharathan, R., Hanson, M., “Diagnostic laparoscopy complicated by group A streptococcal necrotizing fasciitis”, J Minim Invasive Gynecol, 17 (1): 121-123 (2010).

L18.2. Faro, S., Faro, JP., “Necrotizing Soft-tissue Infections in Obstetric and Gynecologic Patients”, Clinical Obstetrics & Gynecology, 55 (4): 875–887 (2012).

L18.3. Chifu, C., Diaconu, C., Andriescu, L., Palaghiu, R., Grigoras, O., Damian, N., “Rare complication of colostomy”, Chirurgia, 101 (4): 433-436 (2007).

L18.4. Kurdoğlu, Z., Akşin, S., Kolusarı, A., “Abdominal histerektomi sonrası insizyon bölgesinde nekrotizan fasit: olgu sunumu”, Anatol J Clin Investig, 5 (4): 186-188 (2011).

L18.5. Campa, MF., Juliana Cano-Mejia, J., Madenjian, R., "A Review of the Pathogenesis of Necrotizing Fasciitis by Group A Streptococci", The Spectra, The Virginia Engineering and Science Research Journal, (2011).

L19. (A10). Sehirali, S., M.M. Inal, Ozsezgin, S., Sanci, M., Atli, O., Nayki, C., Yildirim, Y., Tinar S., “A Randomized Prospective Study of Comparison of Reservoir Ports versus Conventional Vascular Access in Advanced-Stage Ovarian Carcinoma Cases Treated with Chemotherapy”, Int J Gynecol Cancer, 15 (2): 228-232 (2005).

L19.1. Goossens, GA., Stas, M., Jérôme, M., Moons, P., “Systematic review: malfunction of totally implantable venous access devices in cancer patients,” Supportive Care in Cancer, 19 (7): 883-898 (2011).

L19.2. Cahalane, AK., Rassnick, KM., Flanders, JA., “Use of vascular access ports in femoral veins of dogs and cats with cancer”, Journal of the American Veterinary Medical Association, 231 (9): 1354-1360 (2007).

L19.3. Camp-Sorrell, D., “Accessing and Deaccessing Ports: Where Is the Evidence?”, Clinical Journal of Oncology Nursing, 13 (5): 587-590 (2009).

L19.4. David, L., Béatrice, L., Justine, GD., Véronique, LG., Chantal, D., et al. “Clinical Outcome After a Totally Implantable Venous Access Port-Related Infection in Cancer Patients: A Prospective Study and Review of the Literature”, Medicine, 91 (6): 309–318 (2012).

L19.5. Fernández-de-Maya, J., Richart-Martínez, M., “Variability in management of implantable ports in oncology outpatients”, European Journal of Oncology Nursing, 17 (6): 835–840 (2013).

L20. (A5). M.M. Inal, Ertopcu, K., Arici, A., Ozelmas, I., “The Effect of Oral versus Vaginal Misoprostol on Cervical Dilatation in First-trimester Abortion: A Double-blind, Randomized Study”, Eur J Contracept Reprod Health Care, 8 (4): 197-202 (2003).

L20.1. Hussain, A., Ahsan, F., “The vagina as a route for systemic drug delivery”, Journal of Controlled Release, 103 (2): 301–313 (2005).

L20.2. Yan, Z., Kaiyu, T., Lin T., et al. “Effectiveness and Safety of Oral Misoprostol for Cervical Ripening before Artificial Abortion of First-trimester Pregnancy:A Systematic Review”, Journal of practical Obstetrics and Gynecology, 22 (12): (2006).

L20.3. Inal, MM., Yildirim, Y., Ertopcu, K., Ozelmas, I., “The predictors of retained products of conception following first-trimester pregnancy termination with manual vacuum aspiration”, The European Journal of Contraception and Reproductive Health Care, 11 (2): 98-103 (2006).

L20.4. Krishna, SV., Ashok, V., Chatterjee, A., “A Review on Vaginal Drug Delivery Systems”, IJBPAS, 1 (2): 152-167 (2012).

L20.5. Chang-ping, G., Yan, Z., Jing, F., You-ping, L., et al. “Effectiveness and Safety of Vaginal and Sublinguinal Misoprostol for Cervical Ripening before Artificial Abortion of First-Trimester Pregnancy: A Systematic Review”, The Journal of Evidence Based Medicine, 7 (4): (2007).

L21. (A11). Ertopcu, K., M.M. Inal, Ozelmas, I., “Demographic Analysis of Post-Abortive and Interval-Administered Hormonal Contraceptive Methods”, Eur J Contracept Reprod Health Care, 10 (1): 1-5 (2005).

L21.1. Mittal, S., “Contraception after medical abortion”, Contraception, 74 (1): 56–60 (2006).

L21.2. Palanivelu, LM., Oswal, A., “Contraceptive practices in women with repeat termination of pregnancies”, Journal of Obstetrics & Gynaecology, 27 (8): 832-834 (2007).

L21.3. Prata, N., Bell, S., Holston, M., Gerdts, C., Melkamu, Y., “Factors Associated with Choice of Post-Abortion Contraception in Addis Ababa, Ethiopia”, African Journal of Reproductive Health, 15 (3): (2011).

L22.(A7). Yildirim, Y., M.M. Inal, Sanci, M., Sentas, A., Hanhan, M., “Uterine Sarcomas: A 10 Year Experience and A Review of the Literature”, Women’s Oncology Review, 4 (1): 7-12 (2004).

L22.1. Gottwald, L., Gora, E., Korczynski, J., Piekarski, JH., Morawiec, Z., et al. “Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor”, Journal of Obstetrics and Gynaecology Research, 34 (4): 721–725 (2008).

L22.2. Gómez, ASM., Blanco, RG., Loza, RA., Martínez, AS., Lara, HJMM., Zuani, JGZ., “Uterine Sarcoma: Case Report”, Ginecol Obstet Mex, 80 (3): 224-227 (2012).

L22.3. Ertas, IE., Doğan, A., Özdemir, A., Solmaz, U., et al. “The effect of adjuvant treatment modalities on survival outcomes in cytoreductive surgery performed patients with advanced stage uterine sarcomas”, Ege Journal of Medicine, 52 (4): 179-184 (2013).

L23. (A6). Tinar, S., Sehirali, S., M.M. Inal, Yildirim, Y., Celik, E., Yigit, S., “Adenosarcoma of the Uterus: A Case Report”, MedGenMed (electronic resource): Medscape General Medicine, 6 (1): 51 (2004).

L23.1. Rita Sakr, R., Marzouk, P., Bricou, A., Fabien Demaria, F., Annie Cortez, A., Benifla, JL., “Uterine adenosarcoma associated to lymphovascular emboli: a case report”, Cases Journal, 2 (7515): 1-3 (2009).

M. Ulusal kitap yazarlığı veya Ulusal kitaplarda bölüm yazarlığı:

M1. Avcı, ME., M.M. İnal., “Gebelik ve Travma”, Temel Kadın Hastalıkları ve Doğum Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım, s353-362 (2008).

M2. Avcı ME., M.M. İnal., “Sıvı-Elektrolit Dengesi”, Temel Kadın Hastalıkları ve Doğum Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım, s769-777 (2008).

M3. Avcı ME., M.M. İnal., “Premenstrüel Sendrom”, Temel Kadın Hastalıkları ve Doğum Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım, s851-863 (2008).

N. Ulusal Bilimsel Toplantılara Katılım:

N1. Menapoz ve Hormon Replasman Tedavisi 4. Uludağ Sempozyumu, 4-7 Mart 1999, Bursa.

N2. 1. Ulusal Aile Planlaması Kongresi, 14-17 Nisan 1999, Ankara.

N3. 7. Ulusal Perinatoloji Kongresi, 2- 6 Mayıs 1999, Antalya.

N4. 1st Reproductive Medicine 2000, June 7-10, 2000, Istanbul.

N5. 1st International Congress on the Menopause and the 4th National Congress, 17-21 Mayıs 2000, Antalya.

N6. 21st century Reproductive Medicine and Endoscopic Surgery Congress, 14-17 September 2000, Kuşadası, Aydın.

N7. Türk-Alman Jinekoloji Derneği 4. Kongresi, 30 Mayıs- 3 Haziran 2001, Antalya.

N8. 8. Ulusal Jinekolojik Onkoloji Kongresi, 1-5 Mayıs 2002, Antalya.

N9. 1. Ege Jinekolojik Endoskopik Cerrahi Sempozyumu, 13-14 Aralık 2002, İzmir.

N10. 3. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, 20-23 Nisan 2003, Ankara.

N11. Güncel İnfertilite ve Yardımcı Üreme Teknikleri Sempozyumu, 24-27 Nisan 2003, İzmir.

N12. 5. Türk-Alman Jinekoloji Derneği ve 2.Reproductive Medicine Tartışmalı Konular ve Çözümler Ortak Kongresi, 16-20 Mayıs 2003, Antalya.

N13. 4. Ulusal Jinekoloji ve Obstetrik Kongresi, 20-25 Nisan 2004, Antalya.

N14. 9. Ulusal Jinekolojik Onkoloji Kongresi, 4-8 Mayıs 2004, Antalya.

N15. 2. Ege Jinekolojik Endoskopi Sempozyumu ve Workshop, 10-12 Mart 2005, İzmir.

N16. 4. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, 20-23 Nisan 2005, Ankara.

N17. 10. Ulusal Jinekolojik Onkoloji Kongresi, 19-23 Nisan 2006, Antalya.

N18. 5. Ulusal Jinekoloji ve Obstetrik Kongresi, 16-21 Mayıs 2006, Antalya.

N19. Doppler USG ve Obstetri’de Uygulamaları Sempozyumu, 1 Aralık 2006, İzmir.

N20. 6. Ulusal Jinekoloji ve Obstetri Kongresi, 14-19 Mayıs 2008, Antalya.

N21. 10. Ulusal Jinekoloji ve Obstetri Kongresi, 09-13 Mayıs 2012, Antalya.

N22. 5. Ulusal Üreme Endokrinolojisi ve İnfertilite Kongresi, 27-30 Eylül 2012, İzmir.

N23. 13. Ulusal Jinekolojik Onkoloji Kongresi, 07-11 Kasım 2012, Antalya.

O. Eğitim kursu katılımları:

O1. Endokrin Hastalıklarda Laboratuar Değerlendirme Kursu, 30 Nisan – 2 Mayıs 2001, İzmir.

O2. Neonatal Resüsitasyon Kursu, 25-27 Nisan 2001, İzmir.

O3. Fetal Anomaly Scanning Course (ISUOG Outreach Programme), 3 May 1999, Antalya.

Download 248.43 Kb.

Share with your friends:
1   2   3

The database is protected by copyright © 2020
send message

    Main page